Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 12/20 | 0.36 |
| ▸ | IDH1 | O75874 | 5/20 | 0.35 |
| ▸ | INSR | P06213 | 2/20 | 0.33 |
| ▸ | LCK | P06239 | 2/20 | 0.33 |
| ▸ | LTK | P29376 | 2/20 | 0.33 |
| ▸ | AXL | P30530 | 2/20 | 0.33 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.33 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.33 |
| ▸ | MERTK | Q12866 | 2/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 2/20 | 0.33 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | SPR | P35270 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20110774 | 0.88 | ALK (0.35) | ALKIDH1INSRLCKLTK | |
| SCHEMBL17583059 | 0.87 | IDH1 (0.37) | ALKIDH1 | |
| SCHEMBL17583055 | 0.87 | IDH1 (0.37) | ALKIDH1 | |
| SCHEMBL17582769 | 0.84 | ALK (0.35) | ALKIDH1INSRLCKLTK | |
| SCHEMBL17582885 | 0.84 | RAB9A (0.31) | ALKIDH1 | |
| SCHEMBL23559787 | 0.83 | OPRM1 (0.34) | ALKIDH1EGFR | |
| SCHEMBL30543717 | 0.83 | OPRM1 (0.34) | ALKIDH1EGFR | |
| SCHEMBL17586630 | 0.83 | OPRM1 (0.34) | ALKIDH1EGFR | |
| SCHEMBL17582994 | 0.83 | IDH1 (0.32) | IDH1 | |
| SCHEMBL18779249 | 0.75 | EGFR (0.39) | ALKINSRLCKLTKAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12351559-B2 | Benzoimidazol benzomidazol-1,2-yl amides as Kv7 channel activators | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-07-08 | — | — | US | disclosed |
| US-20240300903-A1 | BENZOMIDAZOL-1,2-YL AMDES AS Kv7 CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD (US) | 2024-09-12 | — | — | US | disclosed |
| EP-4289822-A2 | BENZOIMIDAZOL-1,2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (US) | 2023-12-13 | — | — | EP | disclosed |
| EP-4289822-A2 | BENZOIMIDAZOL-1,2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (US) | 2023-12-13 | — | — | EP | disclosed |
| US-11834418-B2 | Benzoimidazol-1,2-yl amides as Kv7 channel activators | BIOHAVEN THERAPEUTICS LTD. (VG) | 2023-12-05 | — | — | US | disclosed |
| US-11724990-B2 | Kv7 channel activators compositions and methods of use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2023-08-15 | — | — | US | disclosed |
| US-11724990-B2 | Kv7 channel activators compositions and methods of use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2023-08-15 | — | — | US | disclosed |
| EP-3572405-B1 | BENZOIMIDAZOL-1,2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | KNOPP BIOSCIENCES LLC (US) | 2023-07-26 | — | — | EP | disclosed |
| US-20230000831-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | CHANNEL BIOSCIENCES, LLC | 2023-01-05 | — | — | US | disclosed |
| US-20210188782-A1 | BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS | CHANNEL BIOSCIENCES, LLC | 2021-06-24 | — | — | US | disclosed |
| US-9914708-B2 | Benzoimidazol-1,2-yl amides as Kv7 channel activators | KNOPP BIOSCIENCES LLC (US) | 2018-03-13 | — | — | US | disclosed |
| US-9914708-B2 | Benzoimidazol-1,2-yl amides as Kv7 channel activators | KNOPP BIOSCIENCES LLC (US) | 2018-03-13 | — | — | US | disclosed |
| US-20170114022-A1 | BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS | CHANNEL BIOSCIENCES, LLC | 2017-04-27 | — | — | US | disclosed |
| US-20170114022-A1 | BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS | CHANNEL BIOSCIENCES, LLC | 2017-04-27 | — | — | US | disclosed |
| US-20170114022-A1 | BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS | CHANNEL BIOSCIENCES, LLC | 2017-04-27 | — | — | US | disclosed |
| US-9481653-B2 | Benzoimidazol-1,2-yl amides as Kv7 channel activators | KNOPP BIOSCIENCES LLC (US) | 2016-11-01 | — | — | US | disclosed |
| US-9481653-B2 | Benzoimidazol-1,2-yl amides as Kv7 channel activators | KNOPP BIOSCIENCES LLC (US) | 2016-11-01 | — | — | US | disclosed |
| US-9481653-B2 | Benzoimidazol-1,2-yl amides as Kv7 channel activators | KNOPP BIOSCIENCES LLC (US) | 2016-11-01 | — | — | US | disclosed |
| US-20160075663-A1 | BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS | CHANNEL BIOSCIENCES, LLC | 2016-03-17 | — | — | US | disclosed |
| US-20160075663-A1 | BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS | CHANNEL BIOSCIENCES, LLC | 2016-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11834418-B2 | Benzoimidazol-1,2-yl amides as Kv7 channel activators | KCNA7, KCNJ2, KCNK17 | ALK 3025/4885IDH1 3023/4885INSR 2947/4885 |
| US-11724990-B2 | Kv7 channel activators compositions and methods of use | KCNA7, KCNK17, KCNAB1 | ALK 2337/4885IDH1 2551/4885INSR 3988/4885 |
| US-20230000831-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | KCNA7, KCNK17, KCNAB1 | ALK 2337/4885IDH1 2551/4885INSR 3988/4885 |
| US-20240300903-A1 | BENZOMIDAZOL-1,2-YL AMDES AS Kv7 CHANNEL ACTIVATORS | KCNA7, KCNK17, KCNK2 | ALK 3242/4885IDH1 4102/4885INSR 3492/4885 |
| US-20170114022-A1 | BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS | KCNA7, KCNJ2, KCNK17 | ALK 3025/4885IDH1 3023/4885INSR 2947/4885 |
| US-20160075663-A1 | BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS | KCNA7, KCNJ2, KCNK17 | ALK 3025/4885IDH1 3023/4885INSR 2947/4885 |
| US-12351559-B2 | Benzoimidazol benzomidazol-1,2-yl amides as Kv7 channel activators | KCNA7, KCNJ2, KCNK17 | ALK 3161/4885IDH1 3145/4885INSR 3329/4885 |
| US-20210188782-A1 | BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS | KCNA7, KCNJ2, KCNK17 | ALK 3025/4885IDH1 3023/4885INSR 2947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.